Results 61 to 70 of about 24,893 (251)

Assessing the Impact of Prophylactic Eculizumab on Renal Graft Survival in Atypical Hemolytic Uremic Syndrome

Transplantation, 2022
Background Atypical hemolytic uremic syndrome (aHUS) is a rare cause of end-stage kidney disease and associated with poor outcomes after kidney transplantation from early disease recurrence.
E. Glover, K. Smith-Jackson, V. Brocklebank, V. Wilson, P. Walsh, Emma K Montgomery, E. Wong, Sally Johnson, M. Malina, D. Kavanagh, N. Sheerin   +10 more
semanticscholar   +1 more source

Epidemiology of Atypical Hemolytic Uremic Syndrome: A Systematic Literature Review

Clinical Epidemiology, 2020
Atypical hemolytic uremic syndrome (aHUS) is a rare but severe disorder that frequently has a genetic component and results from the overactivation of the alternative complement pathway. As research moves toward improved diagnosis and therapy of aHUS, it
K. Yan, K. Desai, L. Gullapalli, E. Druyts, C. Balijepalli   +4 more
semanticscholar   +1 more source

HUS and atypical HUS [PDF]

, 2017
Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy characterized by intravascular hemolysis, thrombocytopenia, and acute kidney failure. HUS is usually categorized as typical, caused by Shiga toxin-producing Escherichia coli (STEC) infection,
Al-Nouri, Allen, Amaral, Ardissino, Arvidsson, Atefi, Atkinson, Berry, Bhakdi, Bhattacharjee, Boltax, Brady, Bresin, Bruneau, Bu, Caires, Campistol, Canalejo, Carson, Chapin, Chien, Cofiell, Cole, Conway, Conway, Coppo, Cornec-Le Gall, de Córdoba, Del Conde, Delvaeye, Dempsey, Devine, Dhakal, Dragon-Durey, Egbor, El-Husseini, Faguer, Fakhouri, Ferreira, Ferreira, Fremeaux-Bacchi, Frimat, George, Gilbert, Gorsuch, Gottschalk, Grabowski, Greenbaum, Hill, Hornung, Hosler, Huber-Lang, Hughson, Hyvärinen, Iida, Ikeda, Jin, Jokiranta, Kang, Karnchanaphanurach, Karpman, Karpman, Karpman, Kavanagh, Keir, Kielstein, Kim, Kourouklaris, Krisinger, Kronbichler, Laurence, Law, Lechner, Lehtinen, Lemaire, Licht, Liszewski, Loirat, Lupu, Manuelian, Martel, Mathew, Matsukuma, Mele, Meri, Morton, Moskovich, Mukhopadhyay, Nakakuma, Nester, Noris, Noris, Noris, Oikonomopoulou, Orth-Höller, Ozaki, Pangburn, Pangburn, Pape, Pecoraro, Pilzer, Podack, Ricklin, Rinder, Rodríguez-Pintó, Roumenina, Ruggenenti, Schutte, Scully, Sethi, Sims, Sinha, Song, Ståhl, Ståhl, Sung, Szilágyi, T. Sakari Jokiranta, Tawadrous, Tedesco, Thomas, Thurman, Toh, Tsai, Tufano, Vasu, Ward, Warwicker, Wehling, Wetsel, Whaley, Wiedmer, Wig, Woodworth, Zipfel, Zipfel   +135 more
core   +1 more source

Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome

Journal of Medical Economics, 2022
Aims This study compared the aggregate duration of treatment administration of approved eculizumab and ravulizumab treatment regimens and resultant productivity implications for patients with atypical hemolytic uremic syndrome (aHUS) and their caregivers.
A. Levy, Peter Chen, K. Johnston, Yan Wang, E. Popoff, I. Tomazos   +5 more
semanticscholar   +1 more source

Case Series of 3 Patients Diagnosed With Atypical Hemolytic Uremic Syndrome Successfully Treated With Steroids, Plasmapheresis, and Rituximab

Canadian Journal of Kidney Health and Disease, 2017
Rationale: Atypical hemolytic uremic syndrome, which has a high probability of chronic kidney disease, morbidity, and mortality, needs to be promptly recognized when patients present with microangiopathic hemolysis.
Jeffery M. Patterson, Lauren Bolster, Loree Larratt   +2 more
doaj   +1 more source

Successful use of eculizumab to treat atypical hemolytic uremic syndrome in patients with inflammatory bowel disease

Thrombosis Journal, 2019
Background Atypical hemolytic uremic syndrome is a rare group of disorders that have in common underlying complement amplifying conditions. These conditions can accelerate complement activation that results in a positive feedback cycle.
Ramy M. Hanna, Noah Merin, Richard M. Burwick, Lama Abdelnour, Umut Selamet, Beshoy Yanny, Patrick Bui, Mary Fouad, Ira Kurtz   +8 more
doaj   +1 more source

Atypical hemolytic uremic syndrome: Consensus of diagnosis and treatment in taiwan.

Journal of the Formosan Medical Association = Taiwan yi zhi, 2022
Atypical hemolytic uremic syndrome (aHUS), characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury, is a rare but life-threatening systemic disorder caused by the dysregulation of the complement pathway.
Min-Hua Tseng, Shih-Hua Lin, J. Tsai, Mai-Szu Wu, I. Tsai, Yeu-Chin Chen, M. Chang, W. Chou, Y. Chiou, Chiu-Ching Huang   +9 more
semanticscholar   +1 more source

Atypical Hemolytic Uremic Syndrome Occurring After Receipt of mRNA-1273 COVID-19 Vaccine Booster: A Case Report

American Journal of Kidney Diseases, 2022
Atypical hemolytic uremic syndrome (aHUS) is a subtype of thrombotic microangiopathy (TMA) characterized by a dysregulation of the alternative complement pathway. Here, we report a previously healthy 38-year-old woman in whom aHUS developed after a COVID-
K. Claes, I. Geerts, W. Lemahieu, A. Wilmer, D. Kuypers, P. Koshy, S. Ombelet   +6 more
semanticscholar   +1 more source

Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency [PDF]

, 2008
Atypical hemolytic uremic syndrome (aHUS) is a severe renal disease that is associated with defective complement regulation caused by multiple factors.
Józsi, Mihály, Licht, C., Richter, H., Strobel, S., Zipfel, S. L.   +4 more
core   +1 more source

Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials

Kidney Medicine
Rationale & Objective Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy (TMA) caused by complement dysregulation. Ravulizumab is a C5i approved for the treatment of aHUS.
B. Dixon, David Kavanagh, Á. M. Aris, Brigitte Adams, Hee Gyung Kang, Edward Wang, Katherine Garlo, M. Ogawa, Praveen Amancha, Sourish Chakravarty, N. Heyne, Seong Heon Kim, S. Cataland, Sung-Soo Yoon, Yoshitaka Miyakawa, Yosu Luque, Melissa Muff-Luett, Kazuki Tanaka, Larry A. Greenbaum   +18 more
semanticscholar   +1 more source